Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity

OBJECTIVE: Letrozole is a non-steroidal aromatase inhibitor (AI) used to treat hormone receptor positive (HR+) breast cancer. Variability in letrozole efficacy and toxicity may be partially attributable to variable systemic drug exposure, which may be influenced by germline variants in the enzymes r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacogenet Genomics
Main Authors: Hertz, Daniel L., Douglas, Julie A., Kidwell, Kelley M., Gersch, Christina L., Desta, Zeruesenay, Storniolo, Ana-Maria, Stearns, Vered, Skaar, Todd C, Hayes, Daniel F, Henry, N. Lynn, Rae, James M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8185249/
https://ncbi.nlm.nih.gov/pubmed/34096894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000429
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados